News
CORT
42.49
+1.21%
0.51
Corcept (CORT) Class Action Alleges Misstatements on FDA Data Concerns - Hagens Berman
PR Newswire · 2d ago
Corcept Therapeutics Incorporated Class Action Reminder – Robbins LLP Encourages CORT Stockholders to Contact the Firm for Information About Their Rights
Barchart · 2d ago
Shareholders Sue Corcept Therapeutics Over Cushing’s Syndrome Drug Claims
TipRanks · 3d ago
Corcept (CORT) Class Action Alleges Misstatements on FDA Data Concerns - Hagens Berman
PR Newswire · 4d ago
Corcept Gains FDA Approval In Ovarian Cancer (Rating Upgrade)
Seeking Alpha · 6d ago
Analysts Are Bullish on Top NA Stocks: Ottobock SE & Co. KGaA (OBCKF), Corcept Therapeutics (CORT)
TipRanks · 6d ago
Weekly Report: what happened at CORT last week (0323-0327)?
Weekly Report · 6d ago
Corcept Therapeutics presents data from Momentum trial at ACC 2026
TipRanks · 03/29 14:55
Corcept MOMENTUM trial finds hypercortisolism in 27.3% of resistant hypertension patients
Reuters · 03/28 18:45
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
Barchart · 03/28 13:45
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
PR Newswire · 03/28 02:25
Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff disposes of 26,198 common shares; value $1,312,000
Reuters · 03/27 20:28
Catalyst (CPRX) Down 2.5% Since Last Earnings Report: Can It Rebound?
NASDAQ · 03/27 15:30
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit
PR Newswire · 03/27 03:04
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
PR Newswire · 03/26 20:42
Corcept Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow Jones · 03/26 15:18
Corcept Therapeutics Price Target Raised to $110.00/Share From $100.00 by Canaccord Genuity
Dow Jones · 03/26 15:18
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $110
Benzinga · 03/26 15:08
Corcept Therapeutics Raised to Peer Perform From Underperform by Wolfe Research
Dow Jones · 03/26 14:27
Wolfe Research Upgrades Corcept Therapeutics to Peer Perform
Benzinga · 03/26 14:17
More
Webull provides a variety of real-time CORT stock news. You can receive the latest news about Corcept Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.